Summary:
The purpose of this research study is to evaluate the safety and tolerability of administering a single IV infusion dose of TAK-925 to adults with Obstructive sleep apnea (OSA) who are experiencing EDS (excessive daytime sleepiness) despite use of a primary OSA therapy. This study is comprised of 1 office visit, 7 overnight/next day stays in our sleep clinic (consecutively), and one phone call over approximately 3-6 weeks. The first visit consists of a physical with our physician, blood draw, ECG, urine specimen collection, urine drug screen, and CPCP compliance. All Study related procedures, physical exams, and study medication are at no cost and qualified participants will receive reimbursement for travel and related expenses for completed study visits.
Qualified Participants Must:
• Be using CPAP, BiPAP, or Auto PAP 3 nights a week for 4 or more hours a night.
•
Have Excessive daytime sleepiness and otherwise be in general good health.
Qualified Participants May Receive:
Compensation for time and travel.